GLP-1 Weight Loss Drugs: The Scientist Behind Ozempic and Wegovy

In this Life Scientific episode, Jens Jul Holst, a pioneer in GLP-1 biology, explains how gut hormones were decoded and GLP-1 inspired drugs that now shape obesity and diabetes treatment. The conversation covers the science, the hurdles of drug design, and the ethical and societal questions around access and long term health. We also learn about Holst’s life path from academic beginnings in Copenhagen to collaborations with industry that pushed the field forward.

• From incretin biology to GLP-1 based therapies
• Overcoming the short half life of GLP-1 via fatty acid modification
• Semaglutide and weekly injections enabling larger weight losses
• Societal questions: access, cost, and health policy

Introduction and GLP-1 background

The podcast opens with a framing of GLP-1 as a gut hormone that helps regulate appetite and glucose. Jens Jul Holst, a physician-scientist whose early work helped decode GLP-1, explains how the incretin concept emerged and how GLP-1 was identified as a critical regulator of insulin secretion and glucagon suppression. The discussion outlines how GLP-1 therapies moved from diabetes treatment to obesity management, highlighting the initial challenges and the pivotal role of biotechnology in turning a natural peptide into a clinically useful drug.

The scientist and the journey

The conversation traces Holst’s life from his Copenhagen upbringing to his medical training and early research career at Bispebjerg Hospital. He describes the academic climate that shaped his view of health and society, and how his lab embraced new technologies such as radioimmunoassay to study gut hormones circulating at very low concentrations. The narrative recounts the collaboration with US and German researchers that culminated in identifying GLP-1 and understanding its dual actions on insulin and glucagon, which laid the foundation for modern GLP-1 therapies.

From diabetes therapy to obesity therapy

Holst explains why GLP-1 peptides, when infused, could normalize glucose in diabetic patients, yet faced a major hurdle for practical obesity therapy: extremely short half life. The enzyme responsible for rapid degradation was identified, and a key breakthrough came from stabilizing GLP-1 by modifying its molecular structure. Novo Nordisk researchers attached a fatty acid chain to GLP-1, extending its half life and enabling once-daily or weekly dosing. This innovation led to early obesity drugs, such as Saxenda, and set the stage for semaglutide based medicines that could last longer in the body and be administered less frequently.

Semaglutide, cardiovascular benefits, and the therapeutic craze

The discussion covers subsequent developments that produced longer-acting GLP-1 agonists like semaglutide, which underpins Ozempic, Wegovy, and related therapies. Higher, carefully titrated doses produced weight losses of up to around 18%, accompanied by surprising cardiovascular benefits. The podcast notes the importance of rigorous clinical trials in revealing reduced adverse cardiovascular events and improved metabolic health, transforming GLP-1 therapy from a diabetes-specific treatment to a broad tool for metabolic health and cardiovascular risk reduction.

Mechanisms, applications, and future directions

Beyond weight loss and glycemic control, Holst outlines emerging research on how GLP-1 drugs influence inflammation and immune pathways, suggesting mechanisms by which these therapies improve organ health in obesity and diabetes. Sleep apnea and other obesity-related conditions show promising responses to GLP-1 therapies. The potential for small molecule GLP-1 agonists and biosimilars could broaden access and lower costs, though policy and funding considerations remain critical. The podcast also discusses the importance of combining pharmacotherapy with lifestyle changes to sustain weight management after stopping medication.

Ethics, access, and policy

Throughout the discussion, the ethical and societal implications of GLP-1 therapies are foregrounded. Issues include cost, equitable access across income groups, and the role of governments in ensuring affordable treatment. Holst reflects on his activist roots and emphasizes that science should benefit the many, not just the few, while recognizing the practical realities of healthcare systems and pharmaceutical development. The conversation closes with a pragmatic view of how society might balance innovation with public health needs.

Closing reflections

Holst reiterates the need for responsible governance and patient-centered care, underscoring that GLP-1 therapies offer meaningful benefits but must be integrated into health systems in ways that maximize public health gains and minimize disparities.